ARGXargenxRunning, no new patients
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Generalized Myasthenia Gravis · gMG · Myasthenia Gravis, Generalized · Myasthenia Gravis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 119 (final count)
- Started
- Apr 16, 2024
- Main results expected
- Jun 30, 2025
- Fully finished
- Jun 2028
- Results posted
- Aug 10, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
MG-ADL Total Score Change From Baseline
Measured over: Up to 29 days in part A
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06298552 · record last updated 2026-08-10 · checked 2026-11-09 15:47 UTC